Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.32 USD | +1.75% | -6.07% | -88.68% |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Apr. 02 | JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 69.07M |
---|---|---|---|---|---|
Net income 2024 * | -81M | Net income 2025 * | -94M | EV / Sales 2024 * | - |
Net cash position 2024 * | 51.8M | Net cash position 2025 * | 82.3M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.9
x | P/E ratio 2025 * |
-0.99
x | Employees | 41 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.06% |
1 day | +1.75% | ||
1 week | -6.07% | ||
Current month | -28.62% | ||
1 month | -25.64% | ||
3 months | -88.10% | ||
6 months | -84.26% | ||
Current year | -88.68% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 17-01-31 | |
Eric Easom
FOU | Founder | 56 | 17-01-31 |
Lucy Day
DFI | Director of Finance/CFO | 65 | 19-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 60 | 17-01-31 | |
Patricia Martin
BRD | Director/Board Member | 63 | 21-03-31 |
Melvin Spigelman
BRD | Director/Board Member | 75 | 22-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +6.26% | - | |
0.00% | 18 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 2.32 | +1.75% | 121,380 |
24-04-25 | 2.28 | -5.00% | 178,962 |
24-04-24 | 2.4 | +1.27% | 44,748 |
24-04-23 | 2.37 | +0.42% | 83,086 |
24-04-22 | 2.36 | -4.45% | 116,269 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-88.68% | 69.07M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ANTX Stock